Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy

Cytotherapy

Volumn 17, Issue 5, 2015, Pages 621-632

  Granzin, Markus ^a,b   Soltenborn, Stephanie ^a   Müller, Sabine ^a   Kollet, Jutta ^a   Berg, Maria ^c   Cerwenka, Adelheid ^b   Childs, Richard W ^c   Huppert, Volker ^a  

^a MILTENYI BIOTEC GMBH   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Automation; CliniMACS Prodigy; Immunotherapy; Natural killer cells; NK cell expansion; NK cell therapy

Indexed keywords

FAS LIGAND; GAMMA INTERFERON; INTERLEUKIN 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR DNAM1; NATURAL KILLER CELL RECEPTOR NKG2D; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ADOPTIVE IMMUNOTHERAPY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; AUTOMATION; CELL ACTIVATION; CELL EXPANSION; CELL FUNCTION; CELL PROLIFERATION; CELL SELECTION; CELL SORTER; CELL TRANSFORMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOLYSIS; DEGRANULATION; EPSTEIN BARR VIRUS; FEEDER CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; IRRADIATION; LEUKEMIA CELL; MAGNETIC ACTIVATED CELL SORTER; MAGNETIC ACTIVATED CELL SORTING; NATURAL KILLER CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TELOMERE; UPREGULATION; CELL CULTURE; CYTOLOGY; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOLOGY; K562 CELL LINE; KINETICS; LYMPHOCYTE ACTIVATION; METABOLISM; PROCEDURES; TELOMERE HOMEOSTASIS;

HUMAN HERPESVIRUS 4;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; AUTOMATION; BIOMARKERS; CELL PROLIFERATION; CELLS, CULTURED; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; IMMUNOTHERAPY, ADOPTIVE; K562 CELLS; KILLER CELLS, NATURAL; KINETICS; LYMPHOCYTE ACTIVATION; TELOMERE HOMEOSTASIS;

EID: 84933524356     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.03.611     Document Type: Article

References (40)

1. Kiessling R., Klein E., Pross H., Wigzell H. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975, 5:117-121.
2. Vivier E., Raulet D.H., Moretta A., Caligiuri M.A., Zitvogel L., Lanier L.L., et al. Innate or adaptive immunity? The example of natural killer cells. Science 2011, 331:44-49.
3. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013, 10:230-252.
4. Stern M., Passweg J.R., Meyer-Monard S., Esser R., Tonn T., Soerensen J., et al. Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT: a prospective phase II study in two centers. Bone Marrow Transplant 2013, 48:433-438.
5. Curti A., Ruggeri L., D'Addio A., Bontadini A., Dan E., Motta M.R., et al. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients. Blood 2011, 118:3273-3279.
6. Miller J.S., Soignier Y., Panoskaltsis-Mortari A., McNearney S.A., Yun G.H., Fautsch S.K., et al. Successful adoptive transfer and invivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005, 105:3051-3057.
7. Geller M.A., Cooley S., Judson P.L., Ghebre R., Carson L.F., Argenta P.A., et al. Aphase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. Cytotherapy 2011, 13:98-107.
8. Bachanova V., Burns L.J., Mckenna D.H., Curtsinger J., Panoskaltsis-Mortari A., Lindgren B.R., et al. Allogeneic natural killer cells for refractory lymphoma. Cytotherapy 2010, 59:1739-1744.
9. Iliopoulou E.G., Kountourakis P., Karamouzis M.V., Doufexis D., Ardavanis A., Baxevanis C.N., et al. Aphase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010, 59:1781-1789.
10. Rubnitz J.E., Inaba H., Ribeiro R.C., Pounds S., Rooney B., Bell T., et al. NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia. JClin Oncol 2010, 28:955-959.
11. Leung W. Infusions of allogeneic natural killer cells as cancer therapy. Clin Cancer Res 2014, 20:3390-3400.
12. Klingemann H.G. Cellular therapy of cancer with natural killer cells-where do we stand?. Cytotherapy 2013, 15:1185-1194.
13. Berg M., Lundqvist A., McCoy P., Samsel L., Fan Y., Tawab A., et al. Clinical-grade exvivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355.
14. Barkholt L., Alici E., Conrad R., Sutlu T., Gilljam M., Stellan B., et al. Safety analysis of exvivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study. Immunotherapy 2009, 1:753-764.
15. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017.
16. Spanholtz J., Preijers F., Tordoir M., Trilsbeek C., Paardekooper J., de Witte T., et al. Clinical-grade generation of active NK cells from cord blood hematopoietic progenitor cells for immunotherapy using a closed-system culture process. PLoS One 2011, 6:e20740.
17. Lapteva N., Durett A.G., Sun J., Rollins L.A., Huye L.L., Fang J., et al. Large-scale exvivo expansion and characterization of natural killer cells for clinical applications. Cytotherapy 2012, 14:1131-1143.
18. Siegler U., Meyer-Monard S., Jorger S., Stern M., Tichelli A., Gratwohl A., et al. Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients. Cytotherapy 2010, 12:750-763.
19. Luhm J., Brand J.M., Koritke P., Hoppner M., Kirchner H., Frohn C. Large-scale generation of natural killer lymphocytes for clinical application. JHematother Stem Cell Res 2002, 11:651-657.
20. Koehl U., Brehm C., Huenecke S., Zimmermann S.-Y., Kloess S., Bremm M., et al. Clinical grade purification and expansion of NK cell products for an optimized manufacturing protocol. Front Oncol 2013, 3:118.
21. Sutlu T., Stellan B., Gilljam M., Quezada H.C., Nahi H., Gahrton G., et al. Clinical-grade, large-scale, feeder-free expansion of highly active human natural killer cells for adoptive immunotherapy using an automated bioreactor. Cytotherapy 2010, 12:1044-1055.
22. Lapteva N., Szmania S.M., van Rhee F., Rooney C.M. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog 2014, 19:121-132.
23. Apel M., Brüning M., Granzin M., Essl M., Stuth J., Blaschke J., et al. Integrated Clinical Scale Manufacturing System for Cellular Products Derived by Magnetic Cell Separation, Centrifugation and Cell Culture. Chemie Ing Tech 2013, 85:103-110.
24. Park K.U., Jin P., Sabatino M., Feng J., Civini S., Khuu H., et al. Gene expression analysis of exvivo expanded and freshly isolated NK cells from cancer patients. JImmunother Hagerst Md 1997 2010, 33:945-955.
25. Fleige S., Pfaffl M.W. RNA integrity and the effect on the real-time qRT-PCR performance. Mol Aspects Med 2006, 27:126-139.
26. Gentleman R.C., Carey V.J., Bates D.M., Bolstad B., Dettling M., Dudoit S., et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004, 5:R80.
27. R Core Team (2013). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL . http://www.R-project.org/.
28. Speed T.P., Bolstad B.M., Irizarry R.A., Astrand M. Acomparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003, 19:185-193.
29. Weng L., Dai H., Zhan Y., He Y., Stepaniants S.B., Bassett D.E. Rosetta error model for gene expression analysis. Bioinformatics 2006, 22:1111-1121.
30. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., et al. TM4 microarray software suite. Methods Enzymol 2006, 411:134-193.
31. Romee R., Foley B., Lenvik T., Wang Y., Zhang B., Ankarlo D., et al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease-17 (ADAM17). Blood 2013, 121:3599-3608.
32. Childs R.W., Berg M. Bringing natural killer cells to the clinic: exvivo manipulation. Hematology Am Soc Hematol Educ Program 2013, 2013:234-246.
33. Lundqvist A., Abrams S.I., Schrump D.S., Alvarez G., Suffredini D., Berg M., et al. Bortezomib and depsipeptide sensitize tumors to tumor necrosis factor-related apoptosis-inducing ligand: a novel method to potentiate natural killer cell tumor cytotoxicity. Cancer Res 2006, 66:7317-7325.
34. Berg M., Childs R. Ex-vivo expansion of NK cells: what is the priority-high yield or high purity?. Cytotherapy 2010, 12:969-970.
35. Parkhurst M.R., Riley J.P., Dudley M.E., Rosenberg S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011, 17:6287-6297.
36. Vanherberghen B., Olofsson P.E., Forslund E., Sternberg-Simon M., Khorshidi M.A., Pacouret S., et al. Classification of human natural killer cells based on migration behavior and cytotoxic response. Blood 2013, 121:1326-1334.
37. Horowitz A., Strauss-Albee D.M., Leipold M., Kubo J., Nemat-Gorgani N., Dogan O.C., et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med 2013, 5:208ra145.
38. Handgretinger R. Negative depletion of CD3(+) and TcRαβ(+) T cells. Curr Opin Hematol 2012, 19:434-439.
39. Iyengar R., Handgretinger R., Babarin-Dorner A., Leimig T., Otto M., Geiger T.L., et al. Purification of human natural killer cells using a clinical-scale immunomagnetic method. Cytotherapy 2003, 5:479-484.
40. Passweg J.R., Tichelli A., Meyer-Monard S., Heim D., Stern M., Kuhne T., et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia 2004, 18:1835-1838.